Castle Biosciences CSTL Proceeds from issuance of common stock relating to employee stock plans
Proceeds from issuance of common stock relating to employee stock plans at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's proceeds from issuance of common stock relating to employee stock plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's proceeds from issuance of common stock relating to employee stock plans?
- Castle Biosciences (CSTL) reported proceeds from issuance of common stock relating to employee stock plans of $1.27M in Q1 2026.
- How has Castle Biosciences's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
- Castle Biosciences's proceeds from issuance of common stock relating to employee stock plans increased by 30.6% year-over-year, from $970K to $1.27M.
- What is the long-term trend for Castle Biosciences's proceeds from issuance of common stock relating to employee stock plans?
- Over 4 years (2021 to 2025), Castle Biosciences's proceeds from issuance of common stock relating to employee stock plans has grown at a 1.1% compound annual growth rate (CAGR), from $2.31M to $2.42M.